Inhibitors of Plasmepsin II-potential antimalarial agents (Publications)
In order to overcome the problem of drug resistance in malaria, it appears wise to concentrate drug discovery efforts toward new structural classes and new mechanisms of action. We report our results,
Clinical Trials at Swiss TPH | Bringing Science to Patients (Page)
https://www.swisstph.ch/fr/services/clinical-trials
Trial for New Malaria Vaccine Malaria persists as a significant challenge in tropical and subtropical regions, prompting the initiation of the SumayaVac-1 study—a clinical trial for a new malaria vaccine known [...] and neonates weighing less than 5kg with acute malaria. The CALINA study is led by Novartis, with the scientific and financial support of Medicines for Malaria Venture (MMV), and is part of the PAMAfrica [...] capacity strengthening activities in public health and malaria, and...
Synthesis of novel diazabicycles and their antiprotozoal activities (Publications)
potencies against Plasmodium falciparum K-1 and Trypanosoma b. rhodesiense, the causative organisms of malaria tropica and the East African form of sleeping sickness
Synthesis and evaluation of beta-carbolinium cations as new antimalarial agents based on pi-delocalized lipophilic cation (DLC) hypothesis (Publications)
efficacy. beta-Carbolinium compounds exhibit medium suppressive activity in vivo against rodent malaria
Antiprotozoal activities of epimeric aminobicycles (Publications)
sleeping sickness, and Plasmodium falciparum K-1, a multiresistant protozoan parasite which causes Malaria tropica. The results are compared to the activities of their formerly synthesized stereoisomers and
Long-lasting and fast-acting<em> in vivo</em> efficacious antiplasmodial azepanylcarbazole amino alcohol (Publications)
With approximately 429,000 deaths in 2016, malaria remains a major infectious disease where the need to treat the fever symptoms, but also to provide relevant post-treatment prophylaxis, is of major importance
Synthesis and evaluation of beta-carbolinium cations as new antimalarial agents based on pi-delocalized lipophilic cation (DLC) hypothesis (Publications)
efficacy. beta-Carbolinium compounds exhibit medium suppressive activity in vivo against rodent malaria
Antiprotozoal activities of epimeric aminobicycles (Publications)
sleeping sickness, and Plasmodium falciparum K-1, a multiresistant protozoan parasite which causes Malaria tropica. The results are compared to the activities of their formerly synthesized stereoisomers and
Synthesis of novel diazabicycles and their antiprotozoal activities (Publications)
potencies against Plasmodium falciparum K-1 and Trypanosoma b. rhodesiense, the causative organisms of malaria tropica and the East African form of sleeping sickness
Long-lasting and fast-acting<em> in vivo</em> efficacious antiplasmodial azepanylcarbazole amino alcohol (Publications)
With approximately 429,000 deaths in 2016, malaria remains a major infectious disease where the need to treat the fever symptoms, but also to provide relevant post-treatment prophylaxis, is of major importance